Insmed Incorporated (INSM) Earnings Call Transcripts
Insmed Incorporated's Latest Earnings Call - June 9, 2026
In the second quarter of fiscal year 2026, Insmed Incorporated reported strong performance driven by the launch of BRINSUPRI, achieving first-quarter sales of $208 million and over 5,000 cumulative prescribers. Despite these positive results, the stock has underperformed, which management attributes to market confusion rather than operational issues. Guidance remains robust, with management projecting over $1 billion in sales for BRINSUPRI in its first year and expressing confidence in continued growth across their product lines, including ARIKAYCE and TPIP.
Reported metrics
| Metric | Value |
|---|---|
| Quarterly Revenue | $208 million (beat) |
| Cumulative Prescribers | 5,000 (positive) |
| New Patient Starts | 7,800 (positive) |
| Projected Peak Sales for BRINSUPRI | $1 billion+ (positive) |
| Patient Discontinuation Rate | 1/3 (neutral) |
| Projected Peak Sales for TPIP | $8 billion (positive) |
Guidance from management
Management maintained guidance for BRINSUPRI to exceed $1 billion in sales in its first year and indicated that they expect continued growth across their product lines, including ARIKAYCE and TPIP, without raising capital in the near term.
What management said
It's our pleasure. And I would just say, I hope everyone understands how enthusiastic we are about where we are as a company. I think there's a major dislocation right now in value versus operational performance, and we hope to continue to educate about that.
What analysts pressed on
Analysts expressed concerns regarding market confusion affecting stock performance despite strong operational metrics. There were also inquiries about the sustainability of patient retention rates and the impact of competition in the therapeutic landscape.
Main topics on the call
- BRINSUPRI Launch Success — Management highlighted that BRINSUPRI is on track for a stellar launch, projecting 'over $1 billion in sales in the first year of launch' with '5,000 cumulative prescribers' and '7,800 new patient starts'. This strong pe...
- Discontinuation Rates — Management noted that discontinuation rates are primarily occurring early in treatment, with about '1/3 of them drop out because of adverse events'. They believe this is manageable and are implementing strategies to impr...
- Market Expansion Opportunities — The addressable market for BRINSUPRI is dynamic, with management indicating that 'the 500,000 patients are growing every year' due to increased diagnoses and exacerbations. They also see significant potential in targetin...
- ARIKAYCE Regulatory Progress — Management is optimistic about the upcoming sNDA filing for ARIKAYCE, aiming for a first-line launch in both the U.S. and Japan next year. They expect strong uptake in Japan due to a higher response rate among the popula...
Read the full Insmed Incorporated transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Insmed Incorporated
Insmed Incorporated (INSM) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 83 calls on record spanning January 16, 2020 to September 14, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 83 Insmed Incorporated earnings call transcripts on record, spanning January 16, 2020 to September 14, 2026. Based on this history, Insmed Incorporated reports quarterly. The most recent call on file is dated September 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- INSM
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 83
- First call
- January 16, 2020
- Most recent
- September 14, 2026
- Reporting cadence
- quarterly